Health Economics›Waldenstroem macroglobulinemia›First-line therapy randomized data

First-line therapy randomized data

Waldenstroem macroglobulinemia · 10 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 5 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ibrutinib and Rituximab Variant #05	—	R 391 307	56d	—	—	—	—	1
Ibrutinib monotherapy Variant #01	—	R 80 133	28d	~44.1 mo	—	~48	~R 3 846 377 PFS proxy · indirect	15
Zanubrutinib monotherapy Variant #01	—	R 65 750	28d	—	—	—	—	4
R-CHOP Variant #23	—	R 59 865	21d	~44.4 mo	—	~65	~R 3 891 219 PFS proxy · indirect	4
Bendamustine and Rituximab (BR) Variant #12	—	R 40 807	28d	~39.6 mo	—	~44	~R 1 795 506 PFS proxy · indirect	18
DRC (SC rituximab) Variant #01 Partial	—	R 12 077	28d	—	—	—	—	—
DRC Variant #01	—	R 12 077	21d	—	—	—	—	—
Fludarabine monotherapy Variant #01	—	R 11 691	28d	~16.5 mo	~52.9 mo	~18	~R 210 435 PFS proxy · indirect	4
Chlorambucil monotherapy Variant #12	—	R 2 523	14d	—	69.8 mo	—	—	—
Rituximab monotherapy N/A - secondary systemic drug	—	R 52	180d	20.3 mo	—	4	R 208 PFS proxy	1

10 of 10 regimens shown